James W. Brush, M.D.

General Partner and Portfolio Manager

Jamie is a General Partner and Portfolio Manager on the Frazier Life Sciences team and co-leads Frazier’s public equity investment strategy.

Jamie joined Frazier Healthcare Partners in 2016 and invests in private and public development stage biotechnology companies. Jamie co-leads the Frazier Life Sciences Public Fund (FLSPF) with Albert Cha and serves as a co-Portfolio Manager for the FLSPF. Jamie led Frazier’s public investments in Trillium Therapeutics (NASDAQ: TRIL; pending acquisition by Pfizer), Translate Bio (NASDAQ: TBIO; acquired by Sanofi Pasteur), Iveric Bio (NASDAQ: ISEE), Rocket Pharmaceuticals (NASDAQ: RCKT), Krystal Biotech (NASDAQ: KRYS), and co-led Frazier’s investments in ARMO (NASDAQ: ARMO; acquired by Eli Lilly), and Ignyta (NASDAQ: RXDX; acquired by Roche). In addition, Jamie represents Frazier on the board of Amunix Pharmaceuticals and Dascena.

Prior to joining Frazier, Jamie was a management consultant with the Boston Consulting Group, where he was a core member of the Healthcare Practice. In this capacity, he led projects involving Biotechnology mergers and acquisitions, R&D, manufacturing, and business development strategy.

Jamie received his M.D. from the University of Southern California, where he was inducted into the Alpha Omega Alpha honors society, and his B.A. from Middlebury College. He completed his post-graduate training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston.

Location
Menlo Park
Education

Middlebury College (B.A.)
University of Southern California (M.D.)

Year Joined
2016
Contact